Granted Patent
B2
US 12,298,307 · App. 18/384,508 · Granted May 13, 2025
PD-ECGF as biomarker of cancer
Inventors:
Oriol Casanovas Casanovas (Barcelona, ES); Gabriela Jiménez Valerio (Barcelona, ES); María Ochoa De Olza (Sant Cugat del Vallès, ES); Valentí Navarro Pérez (Sabadell, ES); Nicklas Bassani (Barcelona, ES); Helena Verdaguer (Barcelona, ES)
Assignees:
FUNDACIÓ INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE BELLVITGE (IDIBELL); INSTITUT CATALÀ D'ONCOLOGIA (ICO)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention corresponds to the field of cancer and is related to predicting cancer detection, diagnosis, monitoring and prediction of response to treatment, in particular platelet derived-endothelial cell growth factor (PD-ECGF) levels for their use as a potential value in monitoring disease evolution and predicting response to anti-angiogenic treatment.
Claims (18)
1. A method for providing an anti-angiogenic treatment to a subject suffering from cancer, the method comprising:
(i) obtaining a sample from the subject, wherein the sample is a tissue sample or a biological fluid sample, and wherein the tissue sample is a sample from a tumor or wherein the biological fluid sample is a sample of blood, serum, or plasma,
(ii) determining a PD-ECGF level in a sample from said subject and,
(iii) comparing the level obtained in (ii) to a reference value, and
(iv) administering the anti-angiogenic treatment to a subject suffering from cancer with a decreased level of PD-ECGF when compared to the reference value,
wherein said anti-angiogenic treatment is not doxorubicin or interferon therapy and wherein the cancer is hepatocellular carcinoma (HCC).
2. The method according to claim 1 , wherein response is measured as early progression of cancer.
3. The method according to claim 1 , wherein the anti-angiogenic treatment is initiated after the determination of the levels of PD-ECGF.
4. The method of claim 1 wherein the tumor is a primary tumor or a metastasis.
5. The method according to claim 1 , wherein the level of PD-ECGF determined is the PD-ECGF protein level.
6. The method according to claim 5 , wherein the PD-ECGF protein level is determined by immunohistochemistry, by ELISA, or by western blot.
7. The method according to claim 1 , wherein the anti-angiogenic treatment comprises an anti-VEGF agent.
8. The method according to claim 7 , wherein the anti-VEGF agent is an anti-VEGF antibody.
9. The method according to claim 8 , wherein the anti-VEGF agent is bevacizumab.
10. The method according to claim 1 , wherein the anti-angiogenic treatment comprises an agent which inhibits the tyrosine kinases stimulated by VEGF.
11. The method according to claim 10 , wherein the agent which inhibits the tyrosine kinases stimulated by VEGF is sunitinib.
12. The method according to claim 1 , wherein the anti-angiogenic treatment comprises a VEGFR2 blocking antibody.
13. The method according to claim 12 , wherein the VEGFR2 blocking antibody is DC101.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 15, 2024
From: CASANOVAS, ORIOL CASANOVAS; DE OLZA, MARIA OCHOA; PEREZ, VALENTI NAVARRO; VERDAGUER, HELENA
To: INSTITUT CATALA D'ONCOLOGIA (ICO)
Reel/Frame 068294/0723 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 15, 2024
From: VALERIO, GABRIELA JIMENEZ; BASSANI, NICKLAS
To: FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE (IDIBELL)
Reel/Frame 068294/0913 →
Priority Claims (1)
EP 15382109
· Mar 11, 2015
· regional
Continuity (2)
Continuation
15556568
References Cited (74)
US 5798213A
· Miyadera et al.
· 1998
[cited by applicant]
US 7611839B2
· Twine et al.
· 2009
[cited by applicant]
US 8029981B2
· Nakamura et al.
· 2011
[cited by applicant]
US 8110675B2
· Chen et al.
· 2012
[cited by applicant]
US 20130178383A1
· Spetzler et al.
· 2013
[cited by applicant]
CN 101993919A
· 2011
[cited by applicant]
EP 0749981A1
· 1996
[cited by applicant]
EP 1510588A1
· 2005
[cited by applicant]
WO 2003086299A2
· 2003
[cited by applicant]
WO 2007115376A1
· 2007
[cited by applicant]
WO 2012129448A1
· 2012
[cited by applicant]
Toi et al., “Significance of Thymidine Phosphorylase as a Marker of Protumor Monocytes in Breast Cancer”, Clinical Cancer Research, 1999, pp. 1131-1137, vol. 5.
[cited by applicant]
Toi et al., “Vascular Endothelial Growth Factor and Platelet-Derived Endothelial Cell Growth Factor Are Frequently Coexpressed in Highly Vascularized Human Breast Cancer”, Clinical Cancer Research, Sep. 1995, pp. 961-96…
[cited by applicant]
Toiyama et al., “Serum miR-21 as a Diagnostic and Prognostic Biomarker in Colorectal Cancer”, Journal of the National Cancer Institute, Jun. 19, 2013, pp. 849-859, vol. 105, Issue 12.
[cited by applicant]
Tsuji et al., “Platelet-Derived Endothelial Cell Growth Factor Expression is an Independent Prognostic Factor in Colorectal Cancer Patients After Curative Surgery”, European Journal of Surgical Oncology, Apr. 1, 2004, p…
[cited by applicant]
Van Der Bilt et al., “Multiple VEGF Family Members are Simultaneously Expressed in Ovarian Cancer: A Proposed Model for Bevacizumab Resistance”, Current Pharmaceutical Design, 2012, pp. 3784-3792, vol. 18.
[cited by applicant]
Vogelstein et al., “Cancer Genes and the Pathways they Control”, Nature Medicine, 2004, pp. 789-799, vol. 10, No. 8.
[cited by applicant]
Volm et al., “Cellular Predictive Factors for the Drug Response of Lung Cancer”, Anti-Cancer Research—International Journal of Cancer Research and Treatment, Sep. 1, 2000, pp. 3449-3458, vol. 20, No. 5B.
[cited by applicant]
Weng et al., “Inhibition of Thymidine Phosphorylase Expression by Using an HSP90 Inhibitor Potentiates the Cytotoxic Effect of Cisplatin in Non-Small-Cell Lung Cancer Cells”, Biochemical Pharmacology, 2012, pp. 126-136,…
[cited by applicant]
Yamamoto et al., “Prediction of the effect of 5′-deoxy-5-fluorouridine by the status of angiogenic enzyme thymidine phosphorylase expression in recurrent breast cancer patients”, Oncology Reports, 1996, pp. 863-865, vol…
[cited by applicant]
Yibin, “The Expression of PD-ECGF, bFGF in Colorectal Cancer and Their Relationship with Microvessel Density (MVD)”, Medical and Health Technology, 2006, 52 pages, No. 1.
[cited by applicant]
Yonenaga et al., “The Expression of Thymidine Phosphorylase/Platelet-Derived Endothelial Cell Growth Factor is Correlated to Angiogenesis in Breast Cancer”, Pathology, 1998, pp. 850-856, vol. 48.
[cited by applicant]
Zhao et al., “Relevance of PD-ECGF with Clinical Pathology and Prognosis of Renal Carcinoma”, Jilin Medical Journal, 2012, 4 pages, vol. 33, No. 1.
[cited by applicant]
“PharmaPoint: Renal Cell Carcinoma—Global Drug Forecast and Market Analysis to 2023”, GlobalData, 2016, 321 pages.
[cited by applicant]
Akizawa et al., “In Vitro and In Vivo Evaluations of a Radioiodinated Thymidine Phosphorylase Inhibitor as a Tumor Diagnostic Agent for Angiogenic Enzyme Imaging”, Nuclear Medicine and Biology, 2010, pp. 427-432, vol. 3…
[cited by applicant]
Balzarini et al., “7-Deazaxanthine, A Novel Prototype Inhibitor of Thymidine Phosphorylase”, FEBS Letters, 1998, pp. 91-95, vol. 438.
[cited by applicant]
Batchelor et al., “AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients”, Cancer Cell, Jan. 2007, pp. 83-95, vol. 11, No. 1.
[cited by applicant]
Bhatt et al., “Cancer Biomarkers—Current Perspectives”, Indian Journal of Medical Research, 2010, pp. 129-149, vol. 132.
[cited by applicant]
Bouïs et al., “Combination of Vascular Endothelial Growth Factor (VEGF) and Thymidine Phosphorylase (TP) to Improve Angiogenic Gene Therapy”, Angiogensis, 2003, pp. 185-192, vol. 6.
[cited by applicant]
Brennan et al., “The Somatic Genomic Landscape of Glioblastoma”, Cell, Oct. 10, 2013, pp. 462-477, vol. 155, No. 2.
[cited by applicant]
Bronckaers et al., “The Dual Role of Thymidine Phosphorylase in Cancer Development and Chemotherapy”, Medicinal Research Reviews, 2009, pp. 903-953, vol. 29, No. 6.
[cited by applicant]
Brostjan et al., “Monitoring of Circulating Angiogenic Factors in Dendritic Cell-Based Cancer Immunotherapy”, Cancer, Nov. 15, 2003, pp. 2291-2301, vol. 98, No. 10.
[cited by applicant]
Clark, “Prognostic Factors Versus Predictive Factors: Examples From a Clinical Trial of Erlotinib”, Molecular Oncology, 2008, pp. 406-412, vol. 1.
[cited by applicant]
Elamin et al., “Thymidine Phosphorylase in Cancer; Enemy or Friend?”, Cancer Microenvironment, Aug. 1, 2015.
[cited by applicant]
Enomoto et al., “Variations in the Expression of Platelet-Derived Endothelial Cell Growth Factor in Human Colorectal Polyps”, Surgery Today, 2000, pp. 711-717, vol. 30.
[cited by applicant]
European Search Report for EP Application 15382109.5 dated Sep. 3, 2015.
[cited by applicant]
Fan et al., “Chronic Exposure of Colorectal Cancer Cells to Bevacizumab Promotes Compensatory Pathways that Mediate Tumour Cell Migration”, British Journal of Cancer, 2011, pp. 1270-1277, vol. 104.
[cited by applicant]
Fischer et al., “Anti-PIGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels”, Cell, Nov. 2, 2007, pp. 463-475, vol. 131.
[cited by applicant]
Fujimoto et al., “Expression of Platelet-Derived Endothelial Cell Growth Factor (PD-ECGF) and its mRNA in Uterine Cervical Cancers”, British Journal of Cancer, Mar. 1, 1999, pp. 1249-1254, vol. 79, No. 7/8.
[cited by applicant]
Fujimoto et al., “The Value of Platelet-derived Endothelial Cell Growth Factor as a Novel Predictor of Advancement of Uterine Cervical Cancers”, Cancer Research, Jul. 1, 2000, pp. 3662-3665, vol. 60.
[cited by applicant]
Fukushima et al., “Structure and Activity of Specific Inhibitors of Thymidine Phosphorylase to Potentiate the Function of Antitumor 2′-Deoxyribonucleosides”, Biochemical Pharmacology, 2000, pp. 1227-1236, vol. 59.
[cited by applicant]
Grierson et al., “Synthesis and In Vitro Evaluation of 5-Fluro-6-[(2-Iminopyrrolidin-1-YL) Methyl]Uracil, TPI(F): An Inhibitor of Human Thymidine Phosphorylase (TP)”, Nucleosides, Nucleotides, and Nucleic Acids, 2010, p…
[cited by applicant]
Hussain et al., “An Investigation of the Kinetic and Anti-Angiogenic Properties of Plant Glycoside Inhibitors of Thymidine Phosphorylase”, Journal of Asian Natural Products Research, Feb. 2009, pp. 159-167, vol. 11, No.…
[cited by applicant]
International Search Report and Written Opinion for PCT/EP2016/055143 dated Apr. 26, 2016.
[cited by applicant]
Italiano, “Prognostic or Predictive? It's Time to Get Back to Definitions!”, Journal of Clinical Oncology, Dec. 10, 2011, pp. 4718-4724, vol. 29, No. 35.
[cited by applicant]
Jahangiri et al., “Biomarkers Predicting Tumor Response and Evasion to Anti-Angiogenic Therapy”, Biochimica et Biophysica Acta, 2012, pp. 86-100, vol. 1825.
[cited by applicant]
Jain et al., “Biomarkers of Response and Resistance to Antiangiogenic Therapy”, National Reviews Clinical Oncology, 2009, pp. 327-338, vol. 6, No. 6.
[cited by applicant]
Jain et al., “The Role of Phosphate in the Action of Thymidine Phosphorylase Inhibitors: Implications for the Catalytic Mechanism”, Bioorganic & Medicinal Chemistry Letters, 2010, pp. 1648-1651, vol. 20.
[cited by applicant]
Jin-No et al., “Circulating Platelet-Derived Endothelial Cell Growth Factor Increases in Hepatocellular Carcinoma Patients”, Cancer, Apr. 1, 1998, pp. 1260-1267, vol. 82, No. 7.
[cited by applicant]
Kim et al., “Overcoming Evasive Resistance from Vascular Endothelial Growth Factor A Inhibition in Sarcomas by Genetic or Pharmacologic Targeting of Hypoxia-Inducible Factor 1a”, International Journal of Cancer, 2013, p…
[cited by applicant]
Liekens et al., “The Nucleoside Derivative 5′-O-Trityl-inosine (KIN59) Suppresses Thymidine Phosphorylase- triggered Angiogenesis via a Noncompetitive Mechanism of Action”, The Journal of Biological Chemistry, Jul. 9, 2…
[cited by applicant]
Lu et al., “Antiangiogenic and Antitumor Activity of 6-(2-Aminoethyl)Amino-5-Chlorouracil, a Novel Small-Molecule Inhibitor of Thymidine Phosphorylase, in Combination with the Vascular Endothelial Growth Factor-Trap”, C…
[cited by applicant]
Manne et al., “Recent Advances in Biomarkers for Cancer Diagnosis and Treatment”, Drug Discovery Today, 2005, pp. 965-976, vol. 10, No. 14.
[cited by applicant]
Metzger et al., “High Basal Level Gene Expression of Thymidine Phosphorylase (Platelet-derived Endothelial Cell Growth Factor) in Colorectal Tumors is Associated with Nonresponse to 5-Fluorouracil”, Clinical Cancer Rese…
[cited by applicant]
Mizutani et al., “Biomarkers in Renal Cell Carcinoma”, Biotherapy, Jan. 1, 2009, pp. 150-157, vol. 23, No. 2.
[cited by applicant]
Mizutani et al., “The Significance of Thymidine Phosphorylase/Platelet-Derived Endothelial Cell Growth Factor Activity in Renal Cell Carcinoma”, Cancer, Aug. 1, 2003, pp. 730-736, vol. 98, No. 4.
[cited by applicant]
Morita et al., “Quantitative Analysis of Thymidine Phosphorylase and Dihydropyrimidine Dehydrogenase in Renal Cell Carcinoma”, Oncology, Aug. 1, 2003, pp. 125-131, vol. 65, No. 2.
[cited by applicant]
Mulrane et al., “Automated Image Analysis in Histopathology: A Valuable Tool in Medical Diagnostics”, Expert Review of Molecular Diagnostics, 2008, pp. 707-725, vol. 8, No. 6.
[cited by applicant]
Office Action for Japanese Application 2017-548041, dated Nov. 26, 2019, 9 pages.
[cited by applicant]
Oldenhuis et al., “Prognostic Versus Predictive Value of Biomarkers in Oncology”, European Journal of Cancer, 2008, pp. 946-953, vol. 44.
[cited by applicant]
Otrock et al., “Is VEGF a Predictive Biomarker to Anti-Angiogenic Therapy?”, Critical Reviews in Oncology/Hematology, 2011, pp. 103-111, vol. 79.
[cited by applicant]
Padrik et al., “Thymidine Phosphorylase as a Prognostic Factor in Renal Cell Carcinoma”, International Urology and Nephrology, Jul. 2, 2009, pp. 295-298, vol. 42, No. 2.
[cited by applicant]
Pula et al., “Proteomics Identifies Thymidine Phosphorylase as a Key Regulator of the Angiogenic Potential of Colony-Forming Units and Endothelial Progenitor Cell Cultures”, Circulation Research, Jan. 2, 2009, pp. 32-40…
[cited by applicant]
Pérez-pérez et al., “Thymidine Phosphorylase Inhibitors: Recent Developments and Potential Therapeutic Applications”, Mini-Reviews in Medicinal Chemistry, 2005, pp. 1113-1123, vol. 5.
[cited by applicant]
Rojo et al., “Review of Imaging Solutions for Integrated Quantitative Immunohistochemistry in the Pathology Daily Practice”, Folia Histochemica Et Cytobiologica, 2009, pp. 349-354, vol. 47, No. 3.
[cited by applicant]
Ruckhaberle et al., “Prognostic Impact of Thymidine Phosphorylase Expression in Breast Cancer Comparison of Microarray and Immunohistochemical Data”, European Journal of Cancer, Feb. 1, 2010, pp. 549-557, vol. 46, No. 3.
[cited by applicant]
Shimada et al., “Prognostic Significance of Serum Thymidine Phosphorylase Concentration in Esophageal Squamous Cell Carcinoma”, American Cancer Society, Mar. 2022, pp. 1947-1954, vol. 94, No. 7.
[cited by applicant]
Supplemental Technical Information filed with the Response to EP Communication, Dec. 17, 2018, 5 pages.
[cited by applicant]
Takahashi et al., “Platelet-Derived Endothelial Cell Growth Factor in Human Colon Cancer Angiogenisis: Role of Infiltrating Cells”, Journal of the National Cancer Institute, Aug. 21, 1996, vol. 88, No. 16.
[cited by applicant]
Takayama et al., “High Levels of Thymidine Phosphorylase as an Independent Prognostic Factor in Renal Cell Carcinoma”, Japanese Journal of Clinical Oncology, Jul. 26, 2006, pp. 564-569, vol. 36, No. 9.
[cited by applicant]
Taylor et al., “Integrative Genomic Profiling of Human Prostate Cancer”, Cancer Cell, Jul. 13, 2010, pp. 11-22, vol. 18.
[cited by applicant]
The Cancer Genome Atlas Research Network, “Comprehensive Molecular Characterization of Clear Cell Renal Cell Carcinoma”, Nature, Jul. 4, 2013, pp. 43-49, vol. 499.
[cited by applicant]
The Cancer Genome Atlas Research Network, Integrated Genomic Characterization of Papillary Thyroid Carcinoma, Cell, Oct. 23, 2014, pp. 676-690, vol. 159.
[cited by applicant]